Status:
COMPLETED
Procalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU
Lead Sponsor:
Hospital Israelita Albert Einstein
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Recently, biomarkers like procalcitonin have been studied in order to help physicians to decrease the duration of the antibiotic therapy. The investigators objective was to assess whether the decrease...
Eligibility Criteria
Inclusion
- all patients admitted in the intensive care unit with sepsis, severe sepsis and septic shock with a microbiologically confirmed infection (blood, urine, tracheal aspirate or bronchoalveolar fluid culture)
Exclusion
- onset of the antibiotic therapy more than 48 hours before the date when the cultures were performed
- patients less than 18 years old
- known pregnancy
- infections requiring prolonged antibotic therapy such as endocarditis, hepatic or brain abscess, deep abscess, mediastinitis and osteomyelitis
- severe infection caused by virus, parasites, fungi or chronic prostatitis
- negative cultures in patients with suspected sepsis, severe sepsis or septic shock
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT01494675
Start Date
March 1 2008
End Date
February 1 2010
Last Update
December 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Israelita Albert Einstein
São Paulo, Sâo Paulo, Brazil, 05641-901